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Abstract
Background: The purpose of this study was to clarify the prognostic significance of peritumoral lymphocyte
infiltration in the capsule of soft tissue sarcomas (STS). Multiple observations in preclinical and clinical studies have
shown that the immune system has a role in controlling tumor growth and progression. Prognostic markers in
potentially curable STS should guide therapy after surgical resection. The immune status at the time of resection
may be important, but the prognostic significance of peritumoral lymphocytes is unknown.
Methods: Tissue microarrays from 80 patients with STS were constructed from duplicate cores of tissue from the
tumor and the peritumoral capsule. Immunohistochemistry was used to evaluate the CD3+, CD4+, CD8+ and CD20
+ lymphocytes in the tumor and the peritumoral capsule.
Results: In univariate analyses, increasing numbers of CD20+ (P = 0.032) peritumoral lymphocytes were associated
with a reduced disease free survival (DSS). In multivariate analyses, a high number of CD20+ peritumoral
lymphocytes (P = 0.030) in the capsule was an independent negative prognostic factor for DSS. There were no
such associations of lymphocyte infiltration in the tumor.
Conclusions: A high density of CD20+ peritumoral lymphocytes is an independent negative prognostic indicator
for patients with STS. Further research is needed to determine whether CD20 cells in the peritumoral capsule of
STS may promote tumor invasion in the surrounding tissue and increase the metastatic potential.
Background
Soft tissue sarcomas (STS) are relatively rare heteroge-
neous malignancies of mesenchymal origin with a high
mortality rate. They comprise less than 1% of adult
malignancies [1]. Approximately 50% of STS patients
will succumb to their disease because of metastasis or
local relapse [2]. There are several prognostic factors
that determine tumour progression and, ultimately, a
patients’ fate. These include tumour grade, size, location,
depth, histological entity, positive resection margins, and
presence of local recurrence [3-9].
There are three groups of tumor infiltrating lympho-
cytes: (a) lymphocytes within cancer cell nests (intratu-
moral lymphocytes); (b) lymphocytes in the central
cancer stroma (stromal lymphocytes), and; (c) lympho-
cytes present along the invasive margins (peritumoral
lymphocytes) [10]. Soft tissue sarcomas are by definition
stromal tumores. But from a biological point of view
any tissue must have both parenchyma and supporting
stroma. For STS it can be both internal tissue and sur-
rounding tissue.
In a previous paper we reported the prognostic sig-
nificance of lymphocyte infiltration in tumors [11].
The purpose of this study was to clarify the prognostic
significance of lymphocyte infiltration in the peritu-
moral capsule of STS patients. This was achieved by
analyzing the expression of CD3+, CD4+, CD8+ and
CD20+ lymphocytes in the peritumoral capsule from
80 patients with non-gastrointestinal stromal tumors
(non-GIST) STS, in relation to other clinico-pathologi-
cal variables.
Stromal cells include (myo)fibroblasts, vascular cells,
infiltrating leukocytes and specialized mesenchymal sup-
port cells unique to each organ microenvironment. Mul-
tiple observations in preclinical and clinical studies
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the immune system may be contradictory because acti-
vation of the adaptive immune system may suppress
malignant cells, whereas activation of various types of
innate immune cells may promote tumor growth [12].
The adaptive immunity is brought about by antigen-spe-
cific T and B-lymphocytes; tumor growth is inhibited
through direct killing by cytotoxic T-lymphocytes, as
well as a combination of cytokine-mediated and anti-
body-mediated tumor cell lysis [12].
CD3 is a part of the T cell receptor (TCR) complex on
mature T lymphocytes. The two major T lymphocyte
subsets are (1) T helper cells (Th, CD4+) and (2) cyto-
toxic T cells (CTL, CD8+). CD4 is a glycoprotein
expressed on the surface of T helper cells and regulatory
T. CD8 is a transmembrane glycoprotein that serves as a
co-receptor for the T cell receptor (TCR). Like the TCR,
CD8 binds to a major histocompatibility complex
(MHC) molecule, but it is specific for the class I MHC
protein. CD20 is a non-glycosylated phosphoprotein
expressed on the surface of all mature B-cells. CD20 is
expressed at all stages of B cell development from pre-
pre B cells through to memory cells (http://www.gene-
cards.org).
It has recently become clear that analysis of the
tumour stroma is paramount. This is because many
anti-tumor effects operate mainly via the tumor stroma
[13], and cancer infiltration by tumor reactive T-lym-
phocytes is required for efficient tumor eradication [14].
However, cancer cells can evade the immune system in
many ways including suppression of cytotoxic T-cells by
regulatory T-cells and by accumulation of myeloid sup-
pressor cells [14-17].
Many studies have been designed to investigate the
prognostic factors of STS using immunohistochemical
methods [18]. Most of the published data has focused
on the expression of markers for cell kinetics and regu-
latory proteins of the cell cycle. There are few studies of
the prognostic impact of lymphocytes in STS [11].
Methods
The National Cancer Data Inspection Board and The
Regional Committee for Research Ethics approved the
study. The material was collected from our approved
biobank for paraffin-embedded materials and slides. The
Regional Committee confirmed that written consent
from the patients for their information to be stored in
the hospital database and used for research was not
needed. This is because most of the material was more
than 10 years old, and most of the patients were dead.
The data was analyzed anonymously.
Primary tumor tissue from patients diagnosed with
STS at the University Hospital of North Norway
(UNN) from 1973 to 2006 and the Hospitals of
Arkhangelsk region, Russia, from 1996-2006 was used
in this retrospective study. 496 potentially suitable
patient records were identified from the hospital data-
base but only 249 of these were eligible because in
they had complete medical records and adequate paraf-
fin-embedded tissue blocks. In 80 of these cases it was
possible to obtain tissue from the peritumoral capsule
for TMA.
This report includes follow-up data for 59 Norwegian
and 21 Russian patients. The median follow-up was 38
(range 0-392) months. Complete demographic and clini-
cal data were collected retrospectively. Formalin-fixed
and paraffin-embedded tumor specimens were obtained
from the archives of the Departments of Pathology at
UNN and Arkhangelsk. The tumors were graded
according to the French Fèdèration Nationales des Cen-
tres de Lutte Contre le Cancer (FNCLCC), [WHO
Tumors of Soft Tissue and bone, 2002]. Wide resection
margins were defined as wide local resection with free
microscopic margins or amputation of the affected limb
or organ. Non-wide resection margins were defined as
either marginal or intra-lesional resection margins, or
no surgery.
The histology of all soft tissue sarcoma cases was
reviewed according to modern classification (WHO,
2002) by two pathologists (AV and SWS). For the Rus-
sian material there were made new slides of all the par-
affin blocks. For the Norwegian material new slides
were made when necessary. All the biopsies were immu-
nostained with CK, CD117, Actin, SMA, VIM and
CD34. Some slides were also stained with S100 if neces-
sary to rule out differential diagnosis. Other molecular
methods where not considered as necessary for differen-
tial diagnostics, but in some cases PCR or FISH were
performed in the initial diagnostics. Ten of the initial
diagnoses were revised due to changes of classification
system and appearance of new entities as GIST. All car-
sinosarcomas, endometrial sarcomas, carcinomas and
lymphomas were excluded.
There is some lymphocyte heterogeneity in tumor and
capsule which gives variation on lymphocyte counts
within tumours. TMAs are therefore not useful to esti-
mate the prognosis of every single patient, but in large
g r o u p st h em e a ne x p r e s s i o nw ill be representative for
the group. In average the heterogeneity will not be a
problem if the sample size is large enough. Usually 60
samples are considered to be enough to get a represen-
tative material. We had two cores from tumor and two
cores from peritumoral capsule from 80 patients. If we
h a du s e dt h r e ec o r e sf r o mt h et u m o ra n dt h r e ec o r e s
from the peritumoral capsule we would secure the
representativeness even more and reduce sampling
errors, but we did not want to use too much tissue from
the donor blocs.
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Tissue microarrays (TMAs) were constructed for high-
throughput molecular pathology research [19-21]. The
slides were evaluated by two pathologists using a light
microscope to identify the peritumoral capsule (AV
and SWS). The most representative areas of the tumor
and the peritumoral capsule were carefully selected
and marked on the hematoxylin and eosin (HE) slides
for the corresponding donor blocks and sampled for
the tissue microarray collector blocks. Soft tissue sar-
comas are by definition stromal tumores. But from a
biological point of view any tissue must have both par-
enchyma and supporting stroma. For STS it can be
both internal tissue and surrounding tissue. Therefore
we have chosen to focus on the tumor capsule (pseu-
docapsule). We defined the peritumoral capsule as the
1-3 mm thick layer of connective tissue surrounding
the parenchyma of the tumor. In high grade tumors
there was no typical capsule, but in several of the
cases it was a desmoplastic reaction in the surrounding
tissues which was also obtained as capsule. The TMAs
were assembled using a tissue-arraying instrument
(Beecher Instruments).
Studies suggest that punching multiple 0.6 mm cores
from different regions captures the heterogeneity of the
capsule more accurately than single 2 to 4 mm cores
[21]. Hence, we used two 0.6-mm cores of the tumor
and two cores from the peritumoral capsule that were
taken from different areas and selected to be as repre-
sentative as possible. To include all core samples, six-
teen tissue array blocks were constructed. Multiple 4-
μm sections were cut with a Micron microtome
(HM355S) and specific antibodies were stained for
immunohistochemistry (IHC).
Immunohistochemistry (IHC)
The applied antibodies were subjected to in-house
validation by the manufacturer for IHC analysis on
paraffin-embedded material. Ventana Benchmark, XT
automated slide stainer (Ventana Medical System,
France) was used for IHC. Sections were de-paraffi-
nized with xylene and rehydrated with ethanol. Anti-
gen retrieval was performed by placing the specimens
in 0.01 M citrate buffer at pH 6.0 and twice exposing
to microwave heating for 10 minutes at 450 W. The
DAKO Envision + System-HRP (DAB) kit was used as
endogen peroxidase blocking. As negative staining
controls, the primary antibodies were replaced with
the primary antibody diluents. Primary mouse mono-
clonal antibodies were incubated for 16 minutes
(CD20, clone L26 Ventana); 20 minutes (CD4, clone 1
F6 Novocastra, dilution 1:5); and 32 minutes (CD8,
clone 1A5 Ventana) at room temperature. The Ven-
tana antibodies were pre-diluted by the manufacturer.
Biotinylated goat anti-mouse IgG and mouse anti-rab-
bit IgM were used as secondary antibodies. The DAB
was used to make the antigens visible. This was fol-
lowed by application of liquid diaminobenzidine and
substratechromogen, yielding a brown reaction pro-
duct at the site of the target antigen. Finally, slides
were counterstained with hematoxylin to make the
nuclei visible. TMA stainingw a sp e r f o r m e di nas i n g l e
experiment for each antibody, including negative
controls.
Scoring of IHC
The ARIOL imaging system (Genetix, San Jose, CA) was
used to scan the slides for antibody staining of the
TMAs. The specimens were scanned at a low resolution
(1.25 ×) and high resolution (20 ×) using an Olympus
BX 61 microscope with an automated platform (Prior).
The slides were loaded in the automated slide loader
(Applied Imaging SL 50). Representative and viable tis-
sue sections from the peritumoral capsule were scored
semi-quantitatively for lymphocyte membrane staining.
For each core the tissues were scored manually on a
computer screen as: 0 (no cells), 1 (1-5 cells), 2 (6-19
cells), or 3 (20+ cells) (Figure 1). We have included all
lymphocytes located within both inner and outer parts
of the capsule. The score for each patient was based on
the mean scorings of cores from the one or several
biopsies. To achieve maximum reproducibility in all
cases every staining was dichotomised (low and high
expression). High expression was defined as mean score
≥ 1 for all the immunomarkers (CD3, CD4, CD8 and
CD20).
Of the 80 patients, we had three missing for immu-
nostaining with CD20. Of the 77 patients with valid
score, a total of 57 patients had the same score in both
cores, and 20 had different scores. When the two cores
from each tumor had different expression, we used the
mean score. If the scores were 0 and 1, the mean score
was 0.5. If the scores were 1 and 2, the mean score was
1.5. In the first case, the mean score was < 1 (low
expression). In the second case, the mean score was > 1
(high expression).
All samples were made anonymous and independently
scored by two pathologists (AV and SWS). Where there
was disagreement, the slides were re-examined and a
consensus was reached by the observers. When assessing
a variable for a given score, the scores of the other vari-
ables, and the outcome, were hidden from the observers.
Statistical methods
Statistical package SPSS (Chicago, IL), version 16 was
used for all statistical analyses. The immunohistochem-
istry scores from each observer were compared for
inter-observer reliability using a two-way random effect
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class correlation coefficient (reliability coefficient) was
obtained from these results.
The Chi-square test and Fishers Exact test were used
to examine the association between molecular marker
expression and various clinicopathological parameters.
Univariate analyses were carried out using the Kaplan-
Meier method, and statistical significance between survi-
val curves was assessed using the log rank test. Disease-
specific survival (DSS) was determined from the date of
histological-confirmed STS diagnosis.
Multivariate analysis was carried out using the Cox
proportional hazards model to assess the independent
impact on survival of each pre-treatment variable in the
presence of other variables. Only variables of significant
value from the univariate analysis were entered into the
Cox regression analysis. Probability for stepwise entry
and removal was set at 0.05 and 0.10, respectively. The
significance level used was p < 0.05.
Results
Clinicopathological variables
Demographic, clinical, and histopathological variables
are shown in Table 1. Patient age range was 0-91 years
(mean 56 years, median 59.5 years), and 44% of the
patients were males. The non-GIST soft tissue sarcomas
(STS) comprised: 20 undifferentiated pleomorphic sar-
coma, 21 leiomyosarcoma, 7 angiosarcoma, 6 liposar-
coma, 6 rhabdomyosarcoma, 6 synovial sarcoma, 5
malignant peripheral nerve sheath tumors (MPNST), 4
malignant fibroblastic/myofibroblastic tumors, and 5
other STS. There were 15 low grade (19%) and 65 high
grade (81%, FNCLCC grade 2 and 3) STS.
Interobserver variability
There was good reproducibility between the two investi-
gating pathologists. Their scoring agreement was tested
for CD8 and CD20. The intra-class correlation coeffi-
cients (reliability coefficients, r) obtained from these
Figure 1 Pictures of tissue cores. IHC microscopic pictures of TMA of soft tissue sarcomas representing different scores for CD8+ and CD20+
lymphocytes in peritumoral capsule. (A) CD8 high score; (B) CD8 low score; (C) CD20 high score; (D) CD20 low score. Original magnification,
×100 and ×400.
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Characteristic Patients
(n)
Patients
(%)
Median survival (months) 5-Year survival
(%)
P
Age
≤ 20 years 7 9 NR 57 0.479
21-60 years 36 45 63 53
> 60 years 37 46 36 44
Sex
Male 35 44 63 50 0.847
Female 45 56 57 49
Nationality
Norwegian 59 74 38 48 0.646
Russian 21 26 127 52
Histology
Undifferentiated pleomorphic sarcoma 20 25 127 57 0.025
Leiomyosarcoma 21 26 67 52
Angiosarcoma 7 9 15 29
Liposarcoma 6 8 36 50
Rhabdomyosarcoma 6 8 32 50
Synovial sarcoma 6 8 31 50
MPNST 5 6 NR 80
MF/MFT 4 5 15 50
Other STS 5 6 11 0
Tumor localization
Extremities 31 39 123 61 0.447
Trunk 15 19 32 47
Retroperitoneum 11 14 57 42
Head/Neck 5 6 15 20
Pelvis 18 23 22 41
Tumor size
≤ 5 cm 26 33 67 54 0.800
5-10 cm 33 41 31 45
>1 0c m 2 0 2 5 8 0 5 3
Missing 1 1
Malignancy grade FNCLCC
1 15 19 NR 70 0.007
23 1 3 9 8 0 6 1
33 4 4 3 1 5 2 9
Tumor depth
Superficial 4 5 NR 100 0.046
Deep 76 95 32 46
Operated
Yes 73 91 75 54 < 0.001
No 7 9 5 0
Surgical margins
Wide 39 49 NR 67 < 0.001
Non-wide 41 51 18 32
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(P < 0.001).
Univariate analysis
Histological entity, malignancy grade, tumor depth, sur-
gery, surgical margins and metastasis at time of diagno-
sis were all significant indicators for disease-free survival
(DSS) in univariate analyses (Table 1).
Increasing numbers of CD20+ (P = 0.032) lympho-
cytes in the peritumoral capsule were significantly asso-
ciated with a reduced DSS. No such relationship was
apparent for CD3+, CD4+ and CD8+ lymphocytes
(Table 2 Figure 2). In subgroup analysis increasing num-
bers of CD20+ lymphocytes were significantly associated
with a reduced DSS in patients over 60 years (P <
0.001), patients with high grade tumors (P = 0.012), and
patients without wide surgical resection margins (P =
0.003) (data not shown). There were no such associa-
tions of lymphocyte infiltration in the tumor (Table 2).
Multivariate analyses
Significant demographic, clinicopathological, and lym-
phocyte infiltrate variables from the univariate analyses
were entered into the multivariate Cox regression analy-
sis. We did not undertake a multivariate analysis of lym-
phocyte counts with CD20 in the tumor, because in this
dataset there was no statistical significance on prognosis
of CD20 counts in the tumor. A high number of CD20
lymphocytes in the peritumoral capsule had an indepen-
dent negative survival impact (HR 2.7, CI95% 1.10-6.60,
Table 1 Clinicopathologic variables and surival. (Continued)
Metastasis at diagnosis
No 65 81 80 57 < 0.001
Yes 15 19 11 14
Chemotherapy
No 59 74 36 46 0.147
Yes 21 26 NR 57
Radiotherapy
No 60 75 38 47 0.775
Yes 20 25 63 55
Prognostic clinicopathologic variables as predictors for disease-specific survival in soft tissue sarcomas with peritumoral capsule (univariate analysis, log rank
test), N = 80 Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; STS, soft tissue
sarcomas; NR, not reached Ninety-one percent (n = 73) underwent surgery. The 5-year survival with non-wide resection margins was 32% and with wide
resection margins it was 67%.
Table 2 Expression of markers and survival.
Tumor Peritumoral capsule
Marker
expression
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year
survival (%)
P Patients
(n)
Patients
(%)
Median survival
(months)
5-Year
survival (%)
P
CD 3
Low 56 70 80 54 0.207 29 36 32 47 0.756
High 19 24 27 36 40 50 67 56
Missing 5 6 11 14
CD 4
Low 64 80 57 49 0.887 45 56 52 51 0.654
High 14 18 27 50 35 44 57 53
Missing 2 3 10 12
CD 8
Low 64 80 80 54 0.198 47 59 67 52 0.838
High 14 18 15 36 26 32 38 50
Missing 2 3 7 9
CD 20
Low 56 70 63 50 0.880 65 81 75 55 0.032
High 22 28 32 50 12 15 13 33
Missing 2 3 3 4
Peritumoral capsule lymphocyte subsets and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test),
N=8 0
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malignancy grade (P = 0.001), surgical operation (P <
0.010), and surgical margins (P < 0.001), (Table 3).
Discussion
In this study, we evaluate the prognostic impact of CD3
+, CD4+, CD8+ and CD20+ lymphocytes in the peritu-
moral capsule and associations with clinico-pathological
variables in 80 non-GIST STS. To our knowledge, this
is the first study of the association between lymphocyte
infiltration in the peritumoral capsule and DSS in STS
patients. Interestingly, high numbers of CD20+ cells in
the capsule was an independent negative prognostic fac-
tor for DSS.
Tumor infiltrating CD20+ B-cells are correlated with
an improved DSS in lung cancer, prostate cancer, ovar-
ian cancer and STS [11,22-25]. Tumor infiltrating lym-
phocytes are considered to be an indication of the host
immune reaction to tumor antigens [26]. Pelletier stu-
died several prognostic factors in 113 NSCLC tumors,
including peritumoral B (CD20+) and T (CD43+) lym-
phocytes, and found B cells to be associated with an
improved DSS [25]. Peritumoral lymphocytes in epithe-
lial tumors may have different significance from lym-
phocytes in the capsule in stromal tumors. In our study,
high numbers of CD20 cells in the capsule were an
independent negative prognostic factor for DSS in STS.
Tumor-associated inflammation is a chronic process
Figure 2 Survival curves. Disease-specific survival curves for CD3+, CD4+, CD8+ and CD20+ lymphocytes in peritumoral capsule in soft tissue
sarcomas.
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pitation of immunoglobulin in the tissue may have a sti-
mulatory effect on the innate immune cells, which may
enhance tumor growth by secreting mediators which sti-
mulate angiogenesis [12]. Many immune cells found in
the tumor microenvironment may be associated with
the tissue disruption caused by inflammatory agents or
they may be a response to tumor growth [27]. In fact,
de Visser et al. showed in an animal model that B lym-
phocytes are required for establishing chronic inflamma-
tory states that promote de novo carcinogenesis [28].
However, it is possible that B regs might accumulate at
the tumor site.
There has been significant progress in cancer immu-
notherapy during the last decade [27]. Progress in
understanding the molecular mechanisms that govern
immune activation, as well as the mechanisms used by
tumor cells to evade surveillance by the immune system,
are advancing the development of immune-mediated
therapies that could be used against a range of human
cancers [29].
Evidence on the role of the immune system in limiting
tumor growth and progression is linked to observations
indicating a positive correlation between the presence of
tumor infiltrating CD8+ T-cells and good prognosis in
various types of cancer [30]. CD8+ cells in malignant
tumors have been associated with an improved DSS in:
non-small cell lung carcinoma; carcinomas of the endo-
metrium, bile duct, colon, oesophagus, and urothelium;
uveal melanoma; and follicular lymphoma [22,31-40].
Tumor infiltrating CD8+ lymphocytes were not asso-
ciated with improved survival in STS [11]. However, in
mice with solid sarcoma EGF-SEA, CD4+, CD8+ and
SEA-reactive T lymphocytes strongly suppressed tumor
growth [41].
T h er o l eo fC D 8 +l y m p h o c y t e si nt h ep e r i t u m o r a l
capsule of STS is unknown. The location of infiltrating
lymphocytes may be important. There are major differ-
ences between 1) lymphocytes within cancer cell nests
in carcinomas (epithelial lymphocytes); 2) lymphocytes
present along the invasive margins (peritumoral lympho-
cytes); and, 3) lymphocytes in the capsule of stromal
tumors such as STS. Galon et al. investigated the rela-
tionship between the type,d e n s i t y ,a n dl o c a t i o no f
immune cells within tumors and the clinical outcome of
patients with colorectal carcinomas. They found that
patients with low densities of CD3+ cells, CD8+ and
CD45RO + memory T cells in both the centre of the
tumor and the invasive margins had a very poor prog-
nosis [32]. High expression of tumor infiltrating CD3+
T-cells is associated with good prognosis in various
types of cancers [30]. High number of CD8+ cytotoxic
T-lymphocytes infiltrating primary and metastatic ovar-
ian cancer sites are associated with improved prognosis
[42]. In our material there was no significant correlation
between DSS and CD3+ or CD8+ infiltrating cells in the
capsule.
The role of CD4+ T and B lymphocytes is controver-
sial in many cancers including STS [30]. In the absence
of CD8+ cytotoxic T cells CD4+ cells are critical, and
sufficient for NKT cell-dependent rejection of experi-
mental tumours [43]. There was a positive correlation
between a high density of CD4+ and CD8+ lymphocytes
in stroma and improved disease-specific survival in non-
small cell lung cancer [22]. In our material we did not
find any significant correlation between DSS and CD4+
infiltrating cells in the capsule.
In a previous paper we reported that high density of
CD20+ lymphocytes in tumor of STS is an independent
positive prognostic indicator in 108 patients with wide
resection margins [11], but not when the 141 patients
with non-wide resection margins were included in the
analysis. In this paper only 39 patients with material
from the peritumoral capsule had wide resection mar-
gins and there was no effect on prognosis of CD20
counts in tumor. However, a high density of CD20+
lymphocytes in the peritumoral capsule is a negative
prognostic indicator for patients with STS, independent
of resection margins.
Table 3 Results of Cox regression analysis in peritumoral
capsule summarizing prognostic factors, N = 80
Factor Hazard Ratio 95% CI P
Tumor size 0.780*
≤ 5 cm 1.000
5-10 cm 1.328 0.601-2.933 0.484
> 10 cm 1.268 0.505-3.186 0.613
Malignancy grade FNCLCC 0.001
1 1.000
2 3.481 0.899-
13.470
0.071
3 8.448 2.285-
31.230
0.001
Operated
Yes 1.000
No 5.594 1.504-
20.812
0.010
Surgical margins
Wide 1.000
Non-wide 3.633 1.768-7.463 < 0.001
Metastasis at time of diagnosis
No 1.000
Yes 2.088 0.977-4.463 0.057
CD20 + cells
Low 1.000
High 2.696 1.102-6.598 0.030
* Overall significance as a prognostic factor
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High density of CD20+ peritumoral lymphocytes is an
independent negative prognostic indicator for patients
with STS. These data need to be verified in larger-scale
studies. Furthermore, experimentally designed research
is required in order to define whether CD20 cells in the
peritumoral capsule of STS promote tumor invasion
and/or metastasis.
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